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肺線維症の病態と治療














The summit: Gilman’s Point 5700m  070809 
Pulse Oxymetry記録 
●貫和のSpO2記録: 
 Sendai（sea level）：96% 
 Mandara Huts（2700m）：85% 
 Horombo Huts（3700m）：78% 
 Kibo Huts（4700m）：63% 
 仮睡後 （4700m）：58% 
 
●貫和の喫煙歴 




 Diamox （125ｍｇ）from 2700m 
 
●帰国後の肺機能検査 












Flow limitation in non-PE 









































































Case 1 (26yo,M,Never) 
Case 2 (31yo,M,Never) 
Case 3 (39yo,M,Never) 
Case 4 (28yo,M,Never) 
Case 5 (61yo,M,BI=200) 
Case 6 (25yo,M,Never) 
Case 7 (37yo,M,Never) 
Case 8 (28yo,M,Never) 
























N Engl J Med. 2009 Jan 8;360(2):140-9.  
Arterial blood gases and oxygen content in climbers 
on Mount Everest. 
Grocott MP, Martin DS, Levett DZ, McMorrow R, 
Windsor J, Montgomery HE; Caudwell  
Xtreme Everest Research Group. 
Centre for Altitude, Space, and Extreme 
Environment Medicine, University College London 
Institute of Human Health and Performance, London, 
United Kingdom. mike.grocott@ucl.ac.uk 
 
BACKGROUND: The level of environmental hypobaric 
hypoxia that affects climbers at the summit of Mount 
Everest (8848 m [29,029 ft]) is close to the limit of 
tolerance by humans. We performed direct field 
measurements of arterial blood gases in climbers 
breathing ambient air on Mount Everest. METHODS: We 
obtained samples of arterial blood from 10 climbers 
during their ascent to and descent from the summit of 
Mount Everest. The partial pressures of arterial oxygen 
(PaO(2)) and carbon dioxide (PaCO(2)), pH, and 
hemoglobin and lactate concentrations were measured. 
The arterial oxygen saturation (SaO(2)), bicarbonate 
concentration, base excess, and alveolar-arterial oxygen 
difference were calculated. RESULTS: PaO(2) fell with 
increasing altitude, whereas SaO(2) was relatively stable. 
The hemoglobin concentration increased such that the 
oxygen content of arterial blood was maintained at or 
above sea-level values until the climbers reached an 
elevation of 7100 m (23,294 ft). In four samples taken at 
8400 m (27,559 ft)--at which altitude the barometric 
pressure was 272 mm Hg (36.3 kPa)--the mean PaO(2) in 
subjects breathing ambient air was 24.6 mm Hg (3.28 kPa), 
with a range of 19.1 to 29.5 mm Hg (2.55 to 3.93 kPa). The 
mean PaCO(2) was 13.3 mm Hg (1.77 kPa), with a range of 
10.3 to 15.7 mm Hg (1.37 to 2.09 kPa). At 8400 m, the mean 
arterial oxygen content was 26% lower than it was at 7100 
m (145.8 ml per liter as compared with 197.1 ml per liter). 
The mean calculated alveolar-arterial oxygen difference 
was 5.4 mm Hg (0.72 kPa). CONCLUSIONS: The elevated 
alveolar-arterial oxygen difference that is seen in subjects 
who are in conditions of extreme hypoxia may represent a 
degree of subclinical high-altitude pulmonary edema or a 
functional limitation in pulmonary diffusion. 














































哺乳類の呼吸器は何が優れているか？Respiration meets evolution 
T rexは有核赤血球を持っていた 
























16w late pseudograndular 
CD34: green 
SMA: red 









































VC:        83 % 
DLco:    40 % 
PO2:      74 Torr 
PCO2:   37 Torr 
Sp-D:   453 
KL-6: 2960  
2002 
62 y.o. 
VC:       99 % 
DLco:   70 % 
PO2:     79 Torr 
PCO2:  41 Torr 
Sp-D:   267 
KL-6: 1460  
1996 
56 y.o. 
     
    67M：1996年検診精査でCT上軽度線維化変化を指摘．定期検査のみで経過． 
        2003年当科外来に紹介．同2月よりプレドニン開始． 
        2004年秋以降頻回の呼吸困難で入退院を繰り返す． 
        2006年より酸素療法．同年暮れ急性増悪．2007年2月末死亡． 
特発性間質性肺炎：検診発見経過例・自覚症状以降予後不良 








































     
1967 第7回日本胸部疾患学会 「間質性肺炎」 
1971 「肺線維症研究会（間質性肺疾患研究会）」 
1974 厚生省特定疾患肺線維症調査研究班 
    原因不明のびまん性間質性肺炎・肺線維症の分類（山中晃） 
 







1994 特発性間質性肺迂遠急性増悪 定義 
1995 治療研究対象疾患：特発性間質性肺炎 







    特定疾患個人票都道府県入力用個人票 




2008  Pirfenidone承認、市販 
 
19c 平滑筋増殖性肺病変（独） 





           UIP, DIP, BIP, LIP, GIP 
1970 diffuse fibrosing alveolitis（英） 
 
1976 Crystal 
           Idiopathic pulmonary fibrosis (IPF) 
 
1985 Epler, Colby 
           bronchiolitis obliterans organizing pneumonia (BOOP) 
1987 Katzenstein 
           acute interstitial pneumonia (AIP) 
 
1994 Katzenstein 
           nonspecific interstitial pneumonia (NSIP) 
 
2000 ATS/ERS  international consensus   
statement   IPF/UIP 
 
2002 ATS/ERS International multudisciplinary 
consensus classification of IIPs 
    
           Microarray analysis of IPF lung 
 
2007  Idiopathic nonspecific interstitial pneumonia: report of 
an American Thoracic Society project. 
 
2008  Acute exacerbations of idiopathic pulmonary fibrosis. 
 
2009  (?) Evidence Based Guidelines on the 




























欧米の研究展開                      日本における研究展開                    背景事象  
特発性間質性肺炎・肺線維症の研究の経過 
腫瘍性肺疾患 



















































  特発性肺線維症(IPF) 












































ATS/ERS International Multidisciplinary Consensus Classification of IIPs. 2002 
特発性間質性肺炎診断と治療の手引き 2004 
びまん性実質性肺疾患の中での特発性間質性肺炎 













UIP NSIP COP/OP AIP/DAD DIP/RB-ILD 
線維化の時相 多彩 一様 一様 一様 一様 
間質への細胞浸潤 少ない 通常多い やや多い 少ない 少ない 
膠原線維増生を伴う 
線維化 















まれ 時々、部分的 多い（小葉中心性） 器質化期以降で時にあり なし 
蜂巣肺 あり まれ なし あり（終末期） なし 
気腔内肺胞 
マクロファージ滲出 





硝子膜形成 なし なし なし あり（滲出期） なし 





特発性間質性肺炎診断と治療の手引き 南江堂 2004 
Katzenstein AL, Myers JL: Am J Respir Crit Care Med, 1998, 157, 1301-15. 
Nagai S, Kitaichi M, Itoh H, et al: Eur Resir J 1998, 12, 1010-19. 
病理医のノートのような、全体像、特徴的局所所見の有無が間質性肺炎組織パターンとして組
織細分類になっている 





  （fibroblastic foci）が多数 
 ４）胸膜近傍で蜂巣肺 





  （特に背側）、肺底部 
２）病変：網状、蜂巣（honeycombing） 
  牽引性気管支拡張症 
  局所的なスリガラス影 





































































Martinez FJ  et al  
The clinical course of patients with idiopathic pulmonary fibrosis.  











Demedts M, et al IFIGENIA Study Group.  
High-dose acetylcysteine in idiopathic pulmonary 
fibrosis. N Engl J Med. 2005 Nov 24;353(21):2229-42. 






/80 cases /75 cases 
欧米における肺線維症急性増悪：最近になり関心 
急性増悪はないとされた欧米にも存在する 
















Acute Exacerbation of IPF 
It is presently unclear if acute exacerbation of IPF is 
simply a manifestation of a respiratory complication 
(such as pulmonary emboli, infection) contributing to an 
acute decline in a patient with IPF or represents a 
spectrum of IPF. Historically, criteria for acute 
exacerbation of IPF have included an unexplained 
worsening of dyspnea within 1 month, evidence of 
hypoxemia as defined by worsened or severely impaired 
gas exchange, new radiographic alveolar infiltrates, and 
an absence of an alternative explanation such as 
infection, pulmonary embolism, pneumothorax, or heart 
failure （Collard,Harold R. 2007）. 
 
Acute exacerbation of IPF histologically  manifests as 
acute or organizing diffuse alveolar damage (DAD), or 
organizing pneumonia in zones of relatively preserved 
lung tissue away from the most fibrotic regions (1674 
Collard,Harold R. 2007). Anecdotal experience indicates 
that sampling issues in some patients may result in 
specimens demonstrating only uncomplicated UIP or the 
organizing phase of DAD without histologic evidence of 
underlying UIP in the sample evaluated (689 
Parambil,Joseph G. 2005）.  
特発性肺線維症急性増悪の定義 



























Ⅰ Ⅱ Ⅲ Ⅳ
60% 18 15 7
12 47% 32 9
4 7 71% 19
1 3 25 70%
新規治療例 315/641 (49.1%) 
更新治療例 564/899 (66.1%) 







Eur J Pharmacol. 2008 Aug 20;590(1-3):400-8.  
Antifibrotic action of pirfenidone and prednisolone: 
different effects on pulmonary cytokines and growth 
factors in bleomycin-induced murine pulmonary fibrosis. 
Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, 






























































































Am J Respir Crit Care Med Vol 171. pp 1040–1047, 2005 
適確例 
年齢20～75 歳． 











PFD 1800 mg (H)  
(n=104) * 
*: <0.1 (vs. Placebo group, Analysis of covariance) 
 





















covariance analysis p-value  
H vs. P: 0.0416 
L vs. P: 0.0394   
H vs. L: not significant 
 
Change in VC (VC) at Week 52 
 The central question is what to make of a change of 0.07 liters in forced vital capacity over 52 
weeks. Does this small a change (although statistically significant) really make a difference to 
patients' lives? The average reader will look at this and think the answer is no. The authors need 

































































0 16 64 196 280 364 
Period (day) 
PFD 1800 mg group (H) 
PFD 1200 mg group (L) 
Placebo group (P) 
 
Mortality during the study: 11 patients (4.1%) in total; 
                                               H group: 3 cases,  L group: 4 cases,  P group: 4 cases 
Log-rank test p-value  
H vs. P: 0.0280 
L vs. P: 0.0655    
H vs. L: not significant  
 
Progression-Free Survival  
Figure 2: The figure suggests that the major change with placebo occurs at around day 80, where a 
sudden drop in progression occurs in the placebo group.  It may be worthwhile for the authors to 
investigate the patients that contribute to the sudden drop around day 80 as a design issue in the study 
that could have caused this difference.  Indeed, besides this sudden drop, the curves remain pretty 
much identical throughout. 
N Engl J Med. 2005 Nov 24;353(21):2229-42.  
High-dose acetylcysteine in idiopathic pulmonary fibrosis. 




N Engl J Med. 2004 Jan 8; 350(2): 125-33.  
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic 
pulmonary fibrosis.   Raghu G, Brown KK, et al King TE Jr; Idiopathic 
Pulmonary Fibrosis Study Group. 
●米国：pirfenidone 臨床試験 CAPACITY 1 & 2 
●米国：その他 ボセンタン、シルデナフィル臨床試験 
CAPACITY 1 (n= 344)  
Pirfenidone (2403mg) : placebo = 1:1  
CAPACITY 2 (n= 435)  
Pirfenidone (2403mg) : placebo:  pirfenidone (1197mg)  = 2: 2 : 1 
●主評価項目であるFVC変化はCAPACITY 2では有意差が






































GWAS：Genome-Wide Association Study 
N Engl J Med. 2007 Mar 29;356(13):1317-26.  
Telomerase mutations in families with idiopathic pulmonary fibrosis. 
Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA 3rd, Lansdorp PM, Greider CW, 
Loyd JE. 
 
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7552-7.  
Adult-onset pulmonary fibrosis caused by mutations in telomerase. 
Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, Weissler JC, Rosenblatt RL, Shay JW, Garcia CK. 










transcriptase delays aging in 
cancer-resistant mice.  
Cell. 2008 ,135(4):609-22. 
J Med Genet. 2008 Oct;45(10):654-6 
A genome-wide association study identifies an association 
of a common variant in TERT with susceptibility to 
idiopathic pulmonary fibrosis.Mushiroda T, 
Wattanapokayakit S, Takahashi A, Nukiwa T, Kudoh S, 
Ogura T, Taniguchi H, Kubo M, Kamatani N, Nakamura Y; 
























Cell. 2008 Nov 14;135(4):609-22. 
Telomerase reverse transcriptase delays 
aging in cancer-resistant mice. 
Tomás-Loba A, Flores I, Fernández-Marcos PJ, 
Cayuela ML, Maraver A, Tejera A, Borrás C, Matheu A, 
Klatt P, Flores JM, Viña J, Serrano M, Blasco MA. 
Telomeres and Telomerase Group, Molecular 
Oncology Program, Spanish National Cancer Centre 
(CNIO), Madrid 28029, Spain. 
 
Telomerase confers limitless proliferative potential to 
most human cells through its ability to elongate 
telomeres, the natural ends of chromosomes, which 
otherwise would undergo progressive attrition and 
eventually compromise cell viability. However, the 
role of telomerase in organismal aging has remained 
unaddressed, in part because of the cancer-
promoting activity of telomerase. To circumvent this 
problem, we have constitutively expressed 
telomerase reverse transcriptase (TERT), one of the 
components of telomerase, in mice engineered 
to be cancer resistant by means of 
enhanced expression of the tumor 
suppressors p53, p16, and p19ARF. In this 
context, TERT overexpression improves the fitness of 
epithelial barriers, particularly the skin and the 
intestine, and produces a systemic delay in aging 
accompanied by extension of the median life span. 
These results demonstrate that constitutive 
expression of Tert provides antiaging 
activity in the context of a mammalian 
organism. 
 
TertはAnti-aging 
御静聴ありがとうございました 
